Krypton

Summary

Krypton (CHEMBL1233877) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 83.8 Da · Kr

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1233877
Name	Krypton
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5416
ChEBI	CHEBI:49695
Molecular formula	Kr
Molecular weight	83.8
InChIKey	DNNSSWSSYDEUBZ-UHFFFAOYSA-N

SMILES: [Kr]

IUPAC name: krypton

Parent form; salt/anhydrous children: CHEMBL1201096

Patent coverage: 38,304 distinct patent families (102,428 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 102,426 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).